Project Details
Description
Investigate the efficacy of newly identified targets induced by anti-angiogenic
treatment in GBM and develop a novel therapeutic alphabody approach.
treatment in GBM and develop a novel therapeutic alphabody approach.
| Acronym | CANBIO (Andres Cano Galiano) |
|---|---|
| Status | Finished |
| Effective start/end date | 15/11/16 → 14/11/20 |
Funding
- FNR - Fonds National de la Recherche: €169,500.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.